| Name | Title | Contact Details |
|---|
Interleukin Genetics Incorporated is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pareto Biotechnologies has pioneered development of a revolutionary synthetic biology platform that produces naturally derived, high value “designer molecules.” Pareto’s technology is the result of over a decade of academic and private sector research and intellectual property focused on one particular polyketide pathway. Building on Dr. Joe Noel’s groundbreaking research at the Salk Institute, this pathway – previously dismissed as the “poor man’s pathway” – is the foundation of Pareto’s platform, capable of generating known products and novel molecules. In the near term, Pareto will introduce “designer molecules” as cosmetics, flavors and fragrances including molecules with properties unlike anything previously experienced. In the long term, Pareto’s molecules will be designed to enhance nutraceuticals, pharmaceuticals, and industrial commodities. Pareto’s potential is limitless. Join us as we ignite a molecular revolution
Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.
Targeting Cancer. Transforming Therapies. Revolutionary science meets transformative cancer therapy Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. In addition to one marketed product, we are advancing a strong product pipeline designed to address significant unmet medical needs.
Advitech is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.